Skip to main content

Table 2 Baseline and outcome characteristics of TB patients receiving placebo in combination with TB drugs for 30 days

From: Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

No. Sex Age Months on ATT
prior to placebo
Dx TB
drugs
regime
Smear
status
Liver size
in cm over normal
Erythrocyte
sedimentation rate (mm/h)
Lymphocytes (%) Leukocytes
(× 109/L)
Hemoglobin
(g/L)
Body weight
(kg)
Total
bilirubin
(μmol/L)
ALT
(mM/h/ml)
       before after before after before after before after before after before after before after before after before after
1 M 22 1 1stDx HRZSE 1 1 1 0 3 6 22 36 6.1 8.7 155 150 74 75 12.1 9.9 0.3 0.3
2 F 35 0 1stDx HRZSE 3 3 1 0 22 41 8 10 8 14.1 75 80 45 45 8.8 8.8 0.4 0.6
3 M 40 0 1stDx HRZSE 1 1 0 1 35 32 12 11 11.8 11.1 158 150 62 62 9.9 9.9 0.4 0.6
4 F 30 0 1stDx HRZSE 1 1 0 1 8 10 21 16 7.2 7.4 126 120 69 69 8.8 14 0.2 0.6
5 M 20 0 1stDx HRZSE 3 3 0 0 50 35 27 26 9.2 10.9 116 110 64 66 8.8 8.8 0.3 0.2
6 M 53 2 RTB HRZSE 2 1 2 1 23 27 19 23 5.5 4.6 86 89 84 86 12.1 8.8 0.3 0.1
7 M 42 0 RTB HRZSE 3 3 1 1 52 49 19 17 10 9.8 113 115 60 61 8.8 8.8 0.1 0.4
8 M 48 0 RTB HRZSE 3 3 0 0 47 38 40 37 11 10.3 139 129 60 61 8.8 17.2 0.1 0.4
9 M 22 1 MDR HRZSE 1 1 1 1 31 20 17 13 8.8 7.7 136 146 70 72 8.8 8.8 0.4 0.6
10 M 36 1 MDR ZAPPtO 1 1 3 3 33 30 27 25 10.1 9.1 107 131 69 69 21 12.1 0.7 1.7
  2/8 Mean
= 34.8
± 3.58
Median
= 35.5
Mean
= 0.5
± 0.7
Median
= 0
   1.9 1.8 0.9
± 0.31
0.8
± 0.29
30.4
± 5.30
28.8
± 4.27
21.2 ±
8.9
21.4
± 9.7
8.77 ±
0.65
9.37 ±
0.80
121.1
± 8.64
122
± 7.69
65.7
± 3.25
66.6
± 3.39
10.79
± 1.21
10.71
± 0.90
0.32
± 0.05
0.55
± 0.14
       P = 0.34 P = 0.68 P = 0.61 P = 0.91 P = 0.43 P = 0.79 P = 0.01 P = 0.96 P = 0.055
  1. TB drugs used in this arm are abbreviated as follows: Izoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Streptomycin (S), Amikacin (A), Para-aminosalicylic acid (P), Prothionamide (Pt), Ofloxacin (O)
\